
1. Nat Commun. 2019 Jan 21;10(1):361. doi: 10.1038/s41467-018-08265-9.

Efficient oral vaccination by bioengineering virus-like particles with protozoan 
surface proteins.

Serradell MC(1), Rupil LL(1)(2), Martino RA(1)(3), Prucca CG(1)(3), Carranza
PG(1)(4), Saura A(1)(2), Fernández EA(1), Gargantini PR(1), Tenaglia AH(1),
Petiti JP(5), Tonelli RR(6), Reinoso-Vizcaino N(7), Echenique J(7), Berod
L(8)(9), Piaggio E(10)(11), Bellier B(10), Sparwasser T(8)(9), Klatzmann D(10),
Luján HD(12)(13).

Author information: 
(1)Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas
(CIDIE), Consejo Nacional de Investigaciones Científicas y Técnicas
(CONICET)/Universidad Católica de Córdoba (UCC), Córdoba, X5016DHK, Argentina.
(2)Facultad de Ciencias de la Salud, Universidad Católica de Córdoba (UCC),
Córdoba, X5004ASK, Argentina.
(3)Centro de Investigaciones en Química Biológica de Córdoba (CIQUBIC),
Departamento de Química Biológica, Facultad de Ciencias Químicas,
CONICET/Universidad Nacional de Córdoba, Córdoba, X5000HUA, Argentina.
(4)Centro de Investigaciones y Transferencia de Santiago del Estero (CITSE),
Facultad de Ciencias Médicas, CONICET/Universidad Nacional de Santiago del
Estero, Santiago del Estero, CP 4200, Argentina.
(5)Instituto de Investigaciones en Ciencias de la Salud (INICSA), Centro de
Microscopía Electrónica, Facultad de Ciencias Médicas, CONICET/Universidad
Nacional de Córdoba, Córdoba, X5000, Argentina.
(6)Departamento de Ciências Farmacêuticas, Instituto de Ciências Ambientais,
Químicas e Farmacêuticas, Universidade Federal de São Paulo, Diadema, CEP
09913-030, Brazil.
(7)Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI),
Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas,
CONICET/Universidad Nacional de Córdoba, Córdoba, X5000HUA, Argentina.
(8)Institute of Infection Immunology, Twincore, Centre for Experimental and
Clinical Infection Research, Hannover Medical School and Helmholtz Centre for
Infection Research, Hannover, 30625, Germany.
(9)Department of Medical Microbiology and Hygiene, University Medical Center of
Mainz, Obere Zahlbacherstr, 6755131 Mainz, Germany.
(10)Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3),
AP-HP, Hôpital Pitié-Salpêtrière, Biotherapy (CIC-BTi) and
Inflammation-Immunopathology-Biotherapy Department (i2B), 75005, Paris, France.
(11)Institut Curie, PSL Research University, INSERM U932, Paris, 75248, France.
(12)Centro de Investigación y Desarrollo en Inmunología y Enfermedades
Infecciosas (CIDIE), Consejo Nacional de Investigaciones Científicas y Técnicas
(CONICET)/Universidad Católica de Córdoba (UCC), Córdoba, X5016DHK, Argentina.
hlujan@ucc.edu.ar.
(13)Facultad de Ciencias de la Salud, Universidad Católica de Córdoba (UCC),
Córdoba, X5004ASK, Argentina. hlujan@ucc.edu.ar.

Intestinal and free-living protozoa, such as Giardia lamblia, express a dense
coat of variant-specific surface proteins (VSPs) on trophozoites that protects
the parasite inside the host's intestine. Here we show that VSPs not only are
resistant to proteolytic digestion and extreme pH and temperatures but also
stimulate host innate immune responses in a TLR-4 dependent manner. We show that 
these properties can be exploited to both protect and adjuvant vaccine antigens
for oral administration. Chimeric Virus-like Particles (VLPs) decorated with VSPs
and expressing model surface antigens, such as influenza virus hemagglutinin (HA)
and neuraminidase (NA), are protected from degradation and activate antigen
presenting cells in vitro. Orally administered VSP-pseudotyped VLPs, but not
plain VLPs, generate robust immune responses that protect mice from influenza
infection and HA-expressing tumors. This versatile vaccine platform has the
attributes to meet the ultimate challenge of generating safe, stable and
efficient oral vaccines.

DOI: 10.1038/s41467-018-08265-9 
PMCID: PMC6341118
PMID: 30664644  [Indexed for MEDLINE]

